Toronto, ON – July 16, 2025 – Dalriada announces a strategic collaboration with an undisclosed, publicly traded computational company specializing in molecular discovery to jointly advance a pipeline of first-in-class and best-in-class targeted therapeutics.

Through this collaboration, Dalriada will leverage its iCLASS platform to uncover cryptic sites and identify novel chemical matter hits for a selection of high-value, challenging therapeutic targets. The collaboration will also explore the integration of Dalriada’s proprietary live-cell, multi-proteomics approach with the collaborator’s computational technologies to evaluate synergies and accelerate drug discovery against otherwise intractable targets.

“We are thrilled to expand our relationship with this partner through a significant collaboration that leverages our iCLASS platform to unlock therapeutic potential against complex targets,” said Diana Kraskouskaya, CEO and Co-founder of Dalriada. “This effort reflects our shared commitment to advancing more effective therapies through complementary innovation.”

Under the terms of the agreement, Dalriada will receive a platform access payment and R&D funding and is eligible for preclinical and clinical milestone payments for each target advanced under the collaboration.

About Dalriada
Dalriada is a small molecule contract research organization (CRO) focused on translationally guided drug discovery, offering end-to-end capabilities to accelerate the development of novel therapeutics.

About the iCLASS Platform
iCLASS is Dalriada’s proprietary multi-(chemo)-proteomics platform that integrates advanced wet-lab and computational technologies to identify druggable pockets and protein–ligand interactions in live-cell environments with site-level precision, enabling discovery of novel therapeutics across the proteome.

Contact:

Email: info@dalriadatx.com

Tel: (1)905-814-5646